Hemostemix Inc. (V:HEM*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: Suite 730; 1015 - 4 St SW
CALGARY AB T2R 1J4
Tel: N/A
Website: https://hemostemix.com
IR: See website
<
Key People
Thomas A. Smeenk
President, Chief Executive Officer, Director
Christina Wu
Interim Chief Financial Officer
 
Business Overview
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient's blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
Financial Overview
For the nine months ended 30 September 2023, Hemostemix Inc revenues was not reported. Net loss decreased 53% to C$1.8M. Lower net loss reflects Professional fees decrease of 74% to C$543K (expense), Consulting and salaries decrease of 31% to C$616K (expense), Stock-based compensation decrease of 98% to C$3K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.06 to -C$0.02.
Reporting Currency: Canadian Dollars
Enterprise value: $8.34M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$2.66M as of Sep 30, 2023
Net annual income (TTM): -$3.17M as of Sep 30, 2023
Free cash flow (TTM): -$2.06M as of Sep 30, 2023
Net Debt Last Fiscal Year: $3.91M as of Sep 30, 2023
Shares outstanding: 87,122,334 as of Oct 20, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.